Roy E. and Merle Meyer Professor of Neuroscience, and director, Peripheral Nerve Research Laboratory, Mayo Clinic
Future Treatment of hATTR Amyloidosis
Analysis of current and newer therapies for the treatment of hereditary ATTR amyloidosis.
Evaluating the Potential of Vultrisiran
Expert discussion on the recent topline results released for vutrisiran in the HELIOS-A trial.
Benefits of TTR Gene Silencers
Discussion on the role of TTR protein stabilizers and gene silencers for treating hereditary ATTR amyloidosis.
Evaluating hATTR Amyloidosis Therapy
Clinicians elaborate on key trial data revealed through the APOLLO and NEURO-TTR studies in hereditary ATTR amyloidosis.
Recent Advances in hATTR Amyloidosis Treatment
Treatment overview of hereditary ATTR amyloidosis and considerations for using newer therapies such as patisiran or inotersen in appropriate patients.
Identification of the Amyloid Protein
The use of mass spectrometry is the gold standard in amyloid proteins.
Tissue Biopsies in hATTR Amyloidosis
Various types of biopsies to diagnosis hereditary ATTR amyloidosis are discussed.
Genetic Testing in hATTR Amyloidosis
Expert panelists provide recommendations for gene panel testing with genetic counseling for evaluation of patients with hereditary ATTR amyloidosis.
Diagnostic Strategies in hATTR Amyloidosis
Diagnostic criteria commonly used to ensure an accurate diagnosis of hereditary ATTR amyloidosis is dissected.
Diabetes and hATTR Amyloidosis Neuropathy
Panelists suggest how to differentiate between diabetic neuropathy and ATTR amyloidosis.
Diagnosing hATTR Amyloidosis
Understanding the diagnostic process in making a ATTR amyloidosis diagnosis.
Signs and Symptoms of hATTR Amyloidosis
Signs and symptoms to help determine a diagnosis of hereditary ATTR.
Disparities in Prevalence of hATTR Amyloidosis
A discussion on understanding the disparities of race and gender in hereditary ATTR amyloidosis.
Prevalence of hATTR Amyloidosis
Analysis on the prevalence of hereditary ATTR amyloidosis.
Overview of hATTR Amyloidosis
Panelists offer an overarching view into hereditary ATTR amyloidosis and differentiate the condition from wild-type ATTR amyloidosis.
2 Clarke Drive Cranbury, NJ 08512